In lung adenocarcinoma, mutations in KRAS can activate the PI3K-STAT3 signaling pathway, thereby inhibiting the expression of miR-34a and leading to elevated expression of CD47, which allows tumor cells to evade immune system surveillance 159. This evidence concerns the gene STAT3 and neoplasm.